# OnCo record nct03381274 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct03381274/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct03381274", "NCT03381274" ;
  schema:name "Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study"@en ;
  schema:description "A phase 1/2 trial of Oleclumab and Osimertinib in non-small-cell lung cancer, run by MedImmune LLC, active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct03381274/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03381274> ;
  onco:status "active" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "1/2" ;
  schema:startDate "2018-05-08" ;
  onco:cancers <https://onco.cc/cancers/nsclc/> ;
  onco:drugs <https://onco.cc/drugs/oleclumab/>, <https://onco.cc/drugs/osimertinib/> ;
  onco:companies <https://onco.cc/companies/astrazeneca/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-nct03381274-j-thorac-oncol-2023/> .